Hao-Han Pang

Dr. Hao-Han Pang

Center for Drug Research and Development, Chang Gung University of Science and Technology, Taoyuan District, Taoyuan, Taiwan
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
NLNan-Si Li
Nan-Si Li
YCYing-Tzu Chen
Ying-Tzu Chen
YHYing-Pei Hsu
Ying-Pei Hsu
Hao-Han PangHao-Han Pang
Hao-Han Pang
CHChiung-Yin Huang
Chiung-Yin Huang
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang

1 January 2019 in Theranostics
Verified
Journal Article
Open access
Hao-Han PangHao-Han Pang
Hao-Han Pang
PCPin-Yuan Chen
Pin-Yuan Chen
KWKuo-Chen Wei
Kuo-Chen Wei
CHChiun-Wei Huang
Chiun-Wei Huang
YSYow-Ling Shiue
Yow-Ling Shiue
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang
Convection-enhanced delivery (CED) is a promising technique for infusing a therapeutic agent directly into the brain, bypassing the blood-brain barrier (BBB) with a pressure gradient to increase drug concentration specifically around the brain tumor, thereby enhancing tumor inhibition and limiting the systemic toxicity of chemotherapeutic agents. Herein, we developed a dual-imaging monitored virus-like nanotherapeutic agent as an ideal CED infusate, which can be delivered to specifically besiege and eradicate brain tumors.

1 October 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
Hao-Han PangHao-Han Pang
Hao-Han Pang
YKYong-Chen Ke
Yong-Chen Ke
NLNan-Si Li
Nan-Si Li
YCYing-Tzu Chen
Ying-Tzu Chen
CHChiung-Yin Huang
Chiung-Yin Huang
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang

1 March 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
YHYing-Pei Hsu
Ying-Pei Hsu
NLNan-Si Li
Nan-Si Li
YCYing-Tzu Chen
Ying-Tzu Chen
Hao-Han PangHao-Han Pang
Hao-Han Pang
KWKuo-Chen Wei
Kuo-Chen Wei
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang

2 April 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Hao-Han PangHao-Han Pang
Hao-Han Pang
CHChiung-Yin Huang
Chiung-Yin Huang
YCYa-Wen Chou
Ya-Wen Chou
CLChia-Jung Lin
Chia-Jung Lin
ZZZi-Lin Zhou
Zi-Lin Zhou
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang
The proof-of-concept strategy in this study based on biodegradable and biocompatible self-assembling fluorescent virus-like particle/RNAi nanocomplexes (VLP/RNAi) produced in Escherichia coli (E. coli) followed by surface modification with a cell-penetrating peptide (CPP) and an apolipoprotein E peptide (ApoEP) (dP@VLP/RNAi), which can cross the blood–brain barrier (BBB) to inhibit the DNA repair mechanism and act synergistically with temozolomide (TMZ) for promoting clinical chemotherapy has achieved good therapeutic effects towards malignant brain tumors. The synergistic value of this study's design was verified in intracranial mouse models of glioblastomas (GBMs). Intravenous administration of this formulation enhanced the curative efficacy of TMZ by downregulating the hepatocyte growth factor receptor (c-MET) gene in GBM U87 cells. Furthermore, upon gene-chemotherapy, the methylated DNA in GBM U87 cells was significantly enhanced by inhibiting the DNA repair mechanism, leading to significant brain tumor suppression. The results of this study could be critical for the design of RNAi-based genetic therapeutics for promoting chemotherapy against brain tumors.

31 March 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
YCYi-Jyun Chen
Yi-Jyun Chen
YHYing-Pei Hsu
Ying-Pei Hsu
You-Lin TainYou-Lin Tain
You-Lin Tain
NLNan-Si Li
Nan-Si Li
Hao-Han PangHao-Han Pang
Hao-Han Pang
Hung-Wei YangHung-Wei Yang
Hung-Wei Yang